Magnetic resonance spectroscopy in Parkinson's disease and parkinsonian syndromes

Functional Neurology

Volumn 22, Issue 2, 2007, Pages 75-79

  Rango, Mario ^a   Arighi, Andrea ^a   Biondetti, Piero ^a   Barberis, Barbara ^a   Bonifati, Cristiana ^a   Blandini, Fabio ^b   Pacchetti, Claudio ^b   Martignoni, Emilia ^c,d   Bresolin, Nereo ^a   Nappi, Giuseppe ^b,e  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^c IRCCS   (Italy)

^d UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Brain; Magnetic resonance spectroscopy; Parkinson's disease

Indexed keywords

4 AMINOBUTYRIC ACID; CHOLINE; CREATININE; GLUTAMIC ACID; GLUTAMINE; INOSITOL; LACTIC ACID; N ACETYLASPARTIC ACID;

ALZHEIMER DISEASE; BRAIN LEVEL; BRAIN SIZE; CORTICOBASAL DEGENERATION; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; EVIDENCE BASED MEDICINE; HUMAN; MAGNETIC FIELD; MITOCHONDRIAL RESPIRATION; NEUROPATHOLOGY; NON INVASIVE MEASUREMENT; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARKINSON DISEASE; PARKINSONISM; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PROGRESSIVE SUPRANUCLEAR PALSY; PROTON NUCLEAR MAGNETIC RESONANCE; SENSITIVITY AND SPECIFICITY; SHORT SURVEY; SHY DRAGER SYNDROME;

ANIMALS; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; PARKINSON DISEASE; PARKINSONIAN DISORDERS;

EID: 34547915571     PISSN: 03935264     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (36)

1. Stern MB, Koller WC. Parkinson's disease. In: Stern MB, Koller WC eds Parkinsonian Syndromes. New York; Marcel Dekker 1993:3-32
2. Beal MF. Experimental models of Parkinson's disease. Nat Rev Neurosci 2001;2:325-334
3. Chan DK, Cordato D, Bui T, Mellick G, Woo J. Comparison of environmental and genetic factors for Parkinson's disease between Chinese and Caucasians. Neuroepidemiology 2004;23:13-22
4. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184
5. Diehl P, Fluck E, Gunter H, Kosfeld R, Seelig J. NMR Basic Principles and Progress. Vol. 28. Berlin, Germany: Springer-Verlag 1992
6. Birken D, Oldendorf WH. N-acetyl-L-aspartic acid: a literature review of a compound prominent in 1H NMR spectroscopic studies of brain. Neurosci Biobehav Rev 1969;13: 23-31
7. Range M, Spagnoli D, Tomei G, Bamonti F, Scalato G, Zetta L. Central nervous system transsynaptic effects of acute axonal injury: a 1H magnetic resonance spectroscopy study. Magn Reson Med 1995;33:595-600
8. Christiansen P, Henriksen O, Stubgaard M, Gideon P, Larsson HB. In vivo quantification of brain metabolites by 1H-MRS using water as an internal standard. Magn Reson Imaging 1993;11:107-118
9. Davie CA, Wenning GK, Barker GJ et al. Differentiation of multiple system atrophy from idiopathic Parkinson's disease using proton magnetic resonance spectroscopy. Ann Neurol 1995;37:204-210
10. O'Neill J, Schuff N, Marks WJ Jr, Feiwell R, Aminoff MJ, Weiner MW. Quantitative 1H magnetic resonance spectroscopy and MRI of Parkinson's disease. Mor Disord 2002;17:917-927
11. Holshouser BA, Komu M, Möller HE et al. Localized proton NMR spectroscopy in the striatum of patients with idiopathic Parkinson's disease: a multicenter pilot study. Magn Reson Med 1995;33:589-594
12. Clarke CE, Lowry M, Horsman A. Unchanged N-acetylaspartate and glutamate in idiopathic Parkinson's disease measured by proton magnetic resonance spectroscopy. Mov Disord 1997;12:297-301
13. Lemmens GM, Ellis C, Williams SCR et al. Proton magnetic resonance spectroscopy in striatonigral degeneration and Parkinson's disease with motor oscillations. Neurology 1996;46:A457 (abstract P06.098)
14. Bandmann O, Sweeney MG, Daniel SE, Marsden CD, Wood NW. Mitochondrial DNA polymorphisms in pathologically proven Parkinson's disease. J Neurol 1997;244:262-265
15. Beal ME Aging, energy, and oxidative stress in neurode-generative diseases. Ann Neurol 1995;38:357-366
16. Beal MF. Commentary on "Alpha-synuclein and mitochondria: a tangled skein". Exp Neurol 2004;186:109-111
17. Benecke R, Strumper P, Weiss H. Electron transfer complexes I and IV of platelets are abnormal in Parkinson's disease but normal in Parkinson-plus syndromes. Brain 1993;116:1451-1463
18. Bradley WG, Daroff RB, Fenichel GM, Jancovich J eds Neurology in Clinical Practice. 3rd edition. Boston, USA; Butterworth-Heinemann 2004
19. Burkhardt C, Kelly JP, Lim YH, Filley CM, Parker WD. Neuroleptic medications inhibit complex I of the electron transport chain. Ann Neurol 1993;33:512-517
20. Haas RH, Nasirian F, Nakano K et al. Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease. Ann Neurol 1995;37:714-722
21. Shoffner JM, Watts RL, Juncos JL, Torroni A, Wallace DC. Mitochondrial oxidative phosphorylation defects in Parkinson's disease. Ann Neurol 1991;30:332-339
22. Bowen BC, Block RE, Sanchez-Ramos J et al. Proton MR spectroscopy of the brain in 14 patients with Parkinson disease. AJNR Am J Neuroradiol 1995;16:61-68
23. Prichard J, Rothman D, Novotny E et al. Lactate rise detected by 1H NMR in human visual cortex during physiological stimulation. Proc Natl Acad Sci USA 1991;81:5829-5831
24. Zijlmans JC, de Koster A, van't Hof MA, Thijssen HO, Horstink MW, Heerschap A. Proton magnetic resonance spectroscopy in suspected vascular ischemic parkinsonism. Acta Neurol Scand 1994;90:405-411
25. Davie CA, Pirtosek Z, Barker GJ, Kingsley DP, Miller DH, Lees AJ. Magnetic resonance spectroscopic study of parkinsonism related to boxing. J Neurol Neurosurg Psychiatry 1995;58:688-691
26. Federico F, Simone IL, Lucivero V et al. Proton magnetic resonance spectroscopy in Parkinson's disease and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 1997;62:239-242
27. Davie CA, Barker GJ, Machado C, Miller DH, Lees AJ. Proton magnetic resonance spectroscopy in Steele-Richardson-Olszewski syndrome. Mov Disord 1997;12: 767-771
28. Tedeschi G, Litvan I, Bonavita A et al. Proton magnetic resonance spectroscopic imaging in progressive supranuclear palsy, Parkinson's disease and corticobasal degeneration. Brain 1997;120:1541-1552
29. O'Neil J, Schuff N, Marks WJ, Feiwell R, Aminoff MJ, Weiner MW. Quantitative 1H magnetic resonance spectroscopy and MRI of Parkinson's disease. Mov Disord 2002;17:917-927
30. Watanabe H, Fukatsu H, Katsuno M et al. Multiple regional 1H-MR spectroscopy in multiple system atrophy: NAA/Cr reduction in pontine base as a valuable diagnostic marker. J Neurol Neurosurg Psychiatry 2004;75:103-109
31. Kantarci K, Petersen RC, Boeve BF et al. 1H MR spectroscopy in common dementias. Natl Med J India 2005;18: 85-86
32. Molina JA, García-Segura JM, Benito-León J et al. Proton magnetic resonance spectroscopy in dementia with Lewy bodies. Eur Neurol 2002;48:158-163
33. Rajput AH, Rozdilsky B, Rajput A. Accuracy of clinical diagnosis in parkinsomism - a prospective study. Can J Neurol Sci 1991;18:275-278
34. Rango M, Canesi M, Ghione I et al. Parkinson's disease, chronic hydrocarbon exposure and striatal neuronal damage: a 1-H MRS study. Neurotoxicology 2006;27:164-168
35. Penn AM, Roberts T, Hodder J, Allen PS, Zhu G, Martin WR. Generalized mitochondrial dysfunction in Parkinson's disease detected by magnetic resonance spectroscopy of muscle. Neurology 1995;45:2097-2099
36. Rango M, Bonifati C, Bresolin N. Parkinson's disease and brain mitochondrial dysfunction: a functional phosphorus magnetic resonance spectroscopy study. J Cereb Blood Flow Metab 2006;26:283-290